{"id":"W193386846","doi":"10.1200/jco.2009.27.15_suppl.598","title":"Phase II trial of neoadjuvant sequential FEC100 followed by docetaxel and capecitabine for HER2-negative locally advanced breast cancer (LABC): A multicenter study from British Columbia","year":2009,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Docetaxel; Taxane; Breast cancer; Internal medicine; Capecitabine; Febrile neutropenia; Epirubicin; Population; Regimen; Oncology; Cyclophosphamide; Breast-conserving surgery; Hazard ratio; Neutropenia; Anthracycline; Surgery; Chemotherapy; Cancer; Mastectomy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002348665,0.001536205,0.00190982,0.0005113368,0.001452507,0.0008208471,0.001519603,0.001137901,0.00418931],"category_scores_gemma":[0.001085077,0.0008601438,0.0006152174,0.0007212324,0.001280187,0.0003791031,0.000528244,0.002186275,0.0009311882],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00431056,"about_ca_system_score_gemma":0.009100168,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.1745496,"about_ca_topic_score_gemma":0.3749736,"domain_scores_codex":[0.9993702,0.0002902892,0.00002119179,0.00008747572,0.00008869199,0.0001423076],"domain_scores_gemma":[0.9987906,0.0001122553,0.00009412154,0.00006370033,0.0001478486,0.000791457],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6442964,0.1362742,0.04601486,0.001146632,0.001777548,0.001265362,0.000938498,0.002455566,0.04424344,0.0001870101,0.01508626,0.1063142],"study_design_scores_gemma":[0.5562046,0.3089747,0.1214708,0.0001013373,0.0009783691,0.0005586706,0.0003593632,0.001568999,0.002391462,0.0001434279,0.007152931,0.00009530017],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.991271,0.0009403436,0.000199019,0.0004784824,0.00004743033,0.00402566,0.001121467,0.00005077964,0.001865782],"genre_scores_gemma":[0.9832394,0.001587104,0.001201811,0.001354138,0.00007774242,0.002895825,0.003107019,0.00002825311,0.006508726],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1745496,"threshold_uncertainty_score":0.3470673,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05665022831420631,"score_gpt":0.4761407311572904,"score_spread":0.4194905028430841,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}